Øystein Karlstad

Senior researcher
Norwegian Institute of Public Health
Oslo, Norway

Leo Pharma (Contracted Research, participation in regulator-mandated phase IV study, with funds paid to his institution (no personal fees) and with no relation to the work reported in this abstract)Novo Nordisk (Contracted Research, participation in regulator-mandated phase IV study, with funds paid to his institution (no personal fees) and with no relation to the work reported in this abstract)

Presentation(s):

• Lisdexamfetamine in Early Pregnancy and Risk of Major Congenital Malformations

  Friday, August 26, 2022
  1:45 PM – 2:00 PM CEST